| 研究报告 |
|
|
|
|
| PEG10基因转染的树突状细胞疫苗对肝癌细胞的杀伤实验研究 |
| 李玲玲1, 周伟2 |
1. 重庆工贸职业技术学院生物化学工程系 重庆 408000;
2. 第三军医大学免疫学研究所 重庆 400038 |
|
| Cytotoxic Study of Dendritic Cell Modified by PEG10 Gene on Liver Cancer Cells |
| LI Ling-ling1, ZHOU Wei2 |
1. Biochemistry Engineering Department, Chongqing Industry &Trade Polytechnic, Chongqing 408000,China;
2. Institute of Immunology,Third Military Medical University, Chongqing 400038,China |
| [1] Derrane M. Gene imprinting: making an impression on cancer research. JNCI J Natl Cancer Inst, 1999, 91 (1): 16-18.
[2] Ono R, Kobayashi S, Wagatsuma H, et al. A retrotransposon-derived gene, PEG10, is a novel imprinted gene located on human chromosome 7q21. Genomics, 2001, 73 (2): 232-237.
[3] Hernandez L, Kozlov S, Piras G, et al. Paternal and maternal genomes confer opposite effects on proliferation, cell-cycle length, senescence, and tumor formation. Proc Nati Acad Sci USA, 2003, 100 (23): 13344-13349.
[4] Noble A, Towne C, Chopin L, et al. Insulin-like growth factor-Ⅱbound to vitronectin enhances MCF-7 breast cancer cell migration. Endocrinology, 2003, 144 (6): 2417-2424.
[5] Moorehead R A, Sanchez O H, Baldwin R M, et al. Transgenic over-expression of IGF-Ⅱinduces spontaneous lung tumors: A model for human lung adenocarcinoma. Oncogene, 2003, 22 (6): 853- 857.
[6] Tsou A P, Chuang Y C, Su J Y, et al. Overexpression of a novel imprinted gene, PEG10, in human hepatocellular carcinoma and in regenerating mouse livers. Biomed Sci, 2003, 10 (6): 625-635.
[7] Okabe H, Satoh S, Furukawa Y, et al. Involvement of PEG10 in human hepatocellular carcinogenesis through interaction with SIAH1. Cancer Res, 2003, 63(12): 3043-3048.
[8] 常莹,陶璐薇,陈孝平,等.肝癌组织中遗传印记基因PEG10表达的特异性及其意义.世界华人消化杂志,2005,13(12): 1408-1411. Chang Y, Tao L W, Chen X P, et al.Word Chin J Digestol, 2005, 13 (12): 1408-1411.
[9] Wang C, Xiao Y, Hu Z, et al. PEG10 directly regulated by E2Fs might have a role in the development of hepatocellular carcinoma. FEBS Lett, 2008, 582 (18): 2793-2798.
[10] Schaefer B C, Schaefer M L, Kappler J W. Observation of antigen-dependent CD8+ T cell/dendritic cell interactions in vivo. Cell Immunol, 2001, 214 (2): 110- 122.
[11] Labarriere N, Bretaudeau L, Gervois N, et al. Apoptotic body-loaded dendritic cells efficiently cross-prime cytotoxic T lymphocytes specific for NA17-A antigen but not for Melan-A/MART-1 antigen. Int J Cancer, 2002, 101 (3): 280-286.
[12] Yamaguchi S, Tatsumi T, Takehara T, et al. Dendritic cell-based vaccines suppress metastatic liver tumor via activation of local innate and acquired immunity. Cancer Immunol Immunother, 2008, 57 (12): 1861-1869.
[13] Brusa D, Garetto S, Chiorino G, et al. Post-apoptotic tumors are more palatable to dendritic cells and enhance their antigen cross-presentation activity. Vaccine, 2008, 26 (50): 6422-6432.
[14] Schuurhuis D H, Verdijk P, Schreibelt G, et al. In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. Cancer Res, 2009, 69(7): 2927-2934.
[15] Tanaka F, Haraguchi N, Isikawa K, et al. Potential role of dendritic cell vaccination with MAGE peptides in gastrointestinal carcinomas. Oncol Rep, 2008, 20 (5): 1111-1116.
[16] Kim J H, Kang T H, Noh K H, et al. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key proapoptotic proteins in cytotoxic CD8 ( + ) T cell-mediated cell death. Immunol Lett, 2009, 122 (1): 58-67. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
